Original title: A Clinical and Angiographic Study of the XIENCE V Everolimus-Eluting Coronary Stent System in the Treatment of Patients With Multivessel Coronary Artery Disease. The EXECUTIVE (EXecutive RCT: Evaluating XIENCE V in a Multi Vessel Disease) Trial. Reference: Flavio Ribichini et al. J Am Coll Cardiol Intv 2013. Article in press. Drug-eluting stents (DES ) have emerged...
Original title: Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: An analysis from the prospective randomized PLATO trial. Reference: Steg PG et al. Circulation. 2013; Epub ahead of print The PLATO study randomized 18624 patients with acute coronary syndrome to receive ticagrelor (180 mg loading dose followed by 90 mg twice daily )...
Original title: Zotarolimus- versus Everolimus-Eluting Stents for Unprotected Left Main Coronary Artery Disease. ISAR-LEFT MAIN 2 Study. Reference: Julinda Mehilli et al. J Am Coll Cardiol, article in press. Improvements in 2nd generation drug-eluting stents led to increased efficiency and safety , however there is little information on these new platforms to treat left main coronary artery ....
Original title: Reduction of Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Rivaroxaban in ATLAS-ACS 2 TIMI 51. Reference: C. Michael Gibson et al. J Am Coll Cardiol 2013;62:286–90. There are few contemporary studies that investigated oral anticoagulation utility in patients with acute coronary syndromes and coronary angioplasty. Rivaroxaban is an oral anticoagulant that directly and...
Original title: Clinical Outcomes of the Resolute Zotarolimus-Eluting Stent in Patients With In-Stent Restenosis Two-Year Results From a Pooled Analysis. Reference: Gert Richardt et al. J Am Coll Cardiol Intv 2013, article in press. Previous studies reported a target lesion revascularization (TLR) of 15% and target vessel (TVR) of 22% after a year of treating an injury-stent restenosis....
Original title: Tissue coverage and neointimal hyperplasia in overlap versus nonoverlap segments of drug-eluting stents 9 to 13 months after implantation: In vivo assessment with optical coherence tomography. Reference: Juan Luis Gutiérrez-Chico et al. Am Heart J 2013;166:83-94.e3. The drug-eluting stent’s (DES) overlapping effect over neointimal healing is not completely understood. Drug overdose, large amounts of polymer and...
Original title: The Independent Value of a Direct Stenting Strategy on Early and Late Clinical Outcomes in Patients Undergoing Elective Percutaneous Coronary Intervention. Reference: Gabriel L. Sardi et al. Catheterization and Cardiovascular Interventions 81:949–956 (2013). The use of direct stenting (DS) without pre-stenting dilation has proven to be a safe strategy, especially with the...
Original title: Deployment of Self-Expandable Stents for Complex Proximal Superficial Femoral Artery Lesions Involving the Femoral Bifurcation With Or Without Jailed Deep Femoral Artery. Reference: Masahiro Yamawaki et al. Catheterization and Cardiovascular Interventions 81:1031–1041 (2013). The endovascular management of chronic total occlusions of the lower extremities has seen great progress over the past years; however, specific segments require...
Original title: Incidence and predictors of stent trombosis: a single-centre study of 5833 consecutive patients undergoing coronary artery stenting Reference: Javaid Iqbal et al. EuroInterventional 2013;9:62-69 Though potentially fatal, stent thrombosis is a low frequency event associated to stent malapposition, fractures, resistance to antiplatelet therapies, and diseases such as diabetes and kidney disease, among other factors. 5883 pacients...